Drug-eluting stent thrombosis after cilostazol withdrawal in a patient previously treated with triple antiplatelet therapy.
Antiplatelet therapy has been shown to reduce cardiac events after coronary stenting. However, despite aggressive antiplatelet therapy, stent thrombosis remains a serious complication of coronary stenting with drug-eluting stent (DES). Although several predictors for DES thrombosis have been suggested by investigators, this serious condition is still not completely preventable now. In particular, patients undergoing non-cardiac surgery or invasive procedures with bleeding risk may interrupt antiplatelet therapy and occasionally experience stent thrombosis. We report a case of DES thrombosis after cilostazol withdrawal for colonoscopic polypectomy in a patient previously treated with triple antiplatelet therapy. The patient presented with acute myocardial infarction but survived after successful emergency coronary revascularization. We discuss a plausible mechanism for DES thrombosis in the described case.
Im
Eui
E
Lee
Sang-Hak
SH
Kim
Jung-Sun
JS
Choi
Donghoon
D
Jang
Yangsoo
Y
D000368:Aged; D000077407:Cilostazol; D003328:Coronary Thrombosis / Q000000981:diagnostic imaging / Q000209:etiology* / Q000517:prevention & control; D013505:Digestive System Surgical Procedures; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011859:Radiography; D013375:Substance Withdrawal Syndrome / Q000000981:diagnostic imaging*; D013777:Tetrazoles / Q000008:administration & dosage / Q000009:adverse effects*
D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077407:Cilostazol